Panitumumab involved 7 positive signals at the SOC level, including “skin and subcutaneous tissue disorders” (ROR=3.9), “blood and lymphatic system disorders” (ROR=3.39), as well as “metabolism and nutrition disorders” (ROR=2.79). The gene discussed is UBXN11; the disease is subcutaneous tissue disorder.